Drug Safety From time to time, the CSEM receives notices about drug safety issues from Health Canada. Current notices: SGLT2 inhibitors – Health Canada warns of potential risks of prolonged or incident DKA despite stopping treatment (August 20, 2024) English Français Nexavar® (sorafenib) – Health Canada assessing the potential risk of tumour lysis syndrome (May 15, 2024) English Français – Health Canada assessing the potential risk of thrombotic microangiopathy (August 10, 2022) English Français Iodinated contrast medium – Health Canada assessing the potential risk of hypothyroidism in children under 3 years of age (May 9, 2024) English Français Taro-Zoledronic acid injection – Recalled because it may contain particulate matter (August 9, 2022) English Français Methadone – Health Canada assessing the potential risk of hypoglycemia (February 8, 2022) English Français Lupron® and Lupron Depot® – Risk of pseudotumor cerebri/idiopathic intracranial hypertension in pediatric patients (January 4, 2022) English Français One lot of Eli Lilly Glucagon – DIN 02243297, lot D239382A, expiry May 10, 2022, recalled September 25, 2021: English Français Dopamine agonist withdrawal syndrome – June 7, 2021: English Français
